Antibody engineering to develop new antirheumatic therapies

Arthritis Research and Therapy

Volumn 11, Issue 3, 2009, Pages

  Isaacs, John D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AGLYCOSYL; ALEMTUZUMAB; ANTIRHEUMATIC AGENT; ATACICEPT; ATLIZUMAB; BELIMUMAB; CERTOLIZUMAB PEGOL; EPRATUZUMAB; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; OCRELIZUMAB; OFATUMUMAB; OKT 3; OTELIXIZUMAB; RITUXIMAB; ROACTEMRA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TEPLIZUMAB; TGN 1412; UNCLASSIFIED DRUG; VISILIZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; CHEMICAL MODIFICATION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DESIGN; DRUG MECHANISM; GRAFT REJECTION; HUMAN; IMMUNOGENICITY; LYMPHOCYTOPENIA; MOLECULAR GENETICS; NONHUMAN; PHAGE DISPLAY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; STRUCTURE ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; BIOSYNTHESIS; DIRECTED MOLECULAR EVOLUTION; GENETICS; IMMUNOLOGY; METHODOLOGY; PROTEIN ENGINEERING; SYNTHESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIRECTED MOLECULAR EVOLUTION; HUMANS; PROTEIN ENGINEERING;

EID: 66149180582     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2594     Document Type: Review

References (72)

1. Junghans RP Anderson CL The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor Proc Natl Acad Sci USA 1996, 93:5512-5516. 39277 8643606 10.1073/pnas.93.11.5512
2. Duncan A Winter G The binding site for C1q on IgG Nature 1988, 332:738-740. 10.1038/332738a0 3258649
3. Duncan A Woof J Partridge L Burton D Winter G Localization of the binding site for the human high-affinity Fc receptor on IgG Nature 1988, 332:563-564. 10.1038/332563a0 2965792
4. Lund J Winter G Jones PT Pound JD Tanaka T Walker MR Artymiuk PJ Arata Y Burton DR Jefferis R Woof JM Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG J Immunol 1991, 147:2657-2662. 1833457
5. Isaacs J Greenwood J Waldmann H Therapy with monoclonal antibodies II. The contribution of Fcg receptor binding and the influence of Ch1 and Ch3 domains on in vivo effector function J Immunol 1998, 161:3863-3869. 9780151
6. Lefranc MP Giudicelli V Ginestoux C Bodmer J Muller W Bontrop R Lemaitre M Malik A Barbie V Chaume D IMGT, the international ImMunoGeneTics database Nucleic Acids Res 1999, 27:209-212. 148137 9847182 10.1093/nar/ 27.1.209
7. Kohler G Milstein C Continuous cultures of fused cells secreting antibody of predefined specificity Nature 1975, 256:495-497. 10.1038/ 256495a0 1172191
8. Herzog C Walker C Pichler W Aeschlimann A Wassmer P Stockinger H Knapp W Rieber P Muller W Monoclonal anti-CD4 in arthritis Lancet 1987, 8573:1461-1462. 2892019 10.1016/S0140-6736(87)91158-5
9. Schroeder TJ First MR Mansour ME Hurtubise PE Hariharan S Ryckman FC Munda R Melvin DB Penn I Ballistreri WF Alexander JW Antimurine antibody formation following OKT3 therapy Transplantation 1990, 49:48-51. 10.1097/ 00007890-199001000-00010 2301026
10. Neuberger MS Williams GT Mitchell EB Jouhal SS Flanagan JG Rabbitts TH A hapten-specific chimaeric IgE antibody with human physiological effector function Nature 1985, 314:268-270. 10.1038/314268a0 2580239
11. Bruggemann M Williams G Bindon C Clark M Walker M Jefferis R Waldmann H Neuberger M Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies J Exp Med 1987, 166:1351-1361. 2189658 3500259 10.1084/jem.166.5.1351
12. Isaacs J Clark M Greenwood J Waldmann H Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential J Immunol 1992, 148:3062-3071. 1578132
13. Wolbink GJ Vis M Lems W Voskuyl AE de Groot E Nurmohamed MT Stapel S Tak PP Aarden L Dijkmans B Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis Arthritis Rheum 2006, 54:711-715. 10.1002/art.21671 16508927
14. Baert F Noman M Vermeire S Van Assche G Haens G Carbonez A Rutgeerts P Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 2003, 348:601-608. 10.1056/NEJMoa020888 12584368
15. Strand V Kimberly R Isaacs JD Biologic therapies in rheumatology: lessons learned, future directions Nat Rev Drug Discov 2007, 6:75-92. 10.1038/nrd2196 17195034
16. Jones PT Dear PH Foote J Neuberger MS Winter G Replacing the complementarity-determining regions in a human antibody with those from a mouse Nature 1986, 321:522-525. 10.1038/321522a0 3713831
17. Clark M Antibody humanization: A case of the 'Emperor's new clothes'? Immunol Today 2000, 21:397-402. 10.1016/S0167-5699(00)01680-7 10916143
18. Isaacs J Watts R Hazleman B Hale G Keogan M Cobbold S Waldmann H Humanised monoclonal antibody therapy for rheumatoid arthritis Lancet 1992, 340:748-752. 10.1016/0140-6736(92)92294-P 1356177
19. Orlandi R Gussow DH Jones PT Winter G Cloning immunoglobulin variable domains for expression by the polymerase chain reaction Proc Natl Acad Sci USA 1989, 86:3833-3837. 287235 2726754 10.1073/pnas.86.10.3833
20. Persson MA Caothien RH Burton DR Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning Proc Natl Acad Sci USA 1991, 88:2432-2436. 51246 1826052 10.1073/pnas.88.6.2432
21. Marks JD Griffiths AD Malmqvist M Clackson TP Bye JM Winter G By-passing immunization: Building high affinity human antibodies by chain shuffling Biotechnology (N Y) 1992, 10:779-783. 10.1038/nbt0792-779 1368267
22. Jespers LS Roberts A Mahler SM Winter G Hoogenboom HR Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen Biotechnology (N Y) 1994, 12:899-903. 10.1038/ nbt0994-899 7521646
23. Griffiths AD Williams SC Hartley O Tomlinson IM Waterhouse P Crosby WL Kontermann RE Jones PT Low NM Allison TJ Prospero TD Hoogenboom HR Nissim A Cox JPL Harrison JL Zaccolo M Gherardi E Winter G Isolation of high affinity human antibodies directly from large synthetic repertoires EMBO J 1994, 13:3245-3260. 395221 8045255
24. McCafferty J Griffiths AD Winter G Chiswell DJ Phage antibodies: filamentous phage displaying antibody variable domains Nature 1990, 348:552-554. 10.1038/348552a0 2247164
25. Bruggemann M Caskey HM Teale C Waldmann H Williams GT Surani MA Neuberger MS A repertoire of monoclonal antibodies with human heavy chains from transgenic mice Proc Natl Acad Sci USA 1989, 86:6709-6713. 297915 2505258 10.1073/pnas.86.17.6709
26. Lonberg N Human antibodies from transgenic animals Nat Biotechnol 2005, 23:1117-1125. 10.1038/nbt1135 16151405
27. Medarex - UltiMAb Human Antibody Development System® http://www.medarex.com/Development/UltiMAb.htm
28. Lonberg N Fully human antibodies from transgenic mouse and phage display platforms Curr Opin Immunol 2008, 20:450-459. 10.1016/j.coi.2008.06.004 18606226
29. Nesbitt A Fossati G Bergin M Stephens P Stephens S Foulkes R Brown D Robinson M Bourne T Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents Inflamm Bowel Dis 2007, 13:1323-1332. 10.1002/ibd.20225 17636564
30. Dillon SR Gross JA Ansell SM Novak AJ An APRIL to remember: Novel TNF ligands as therapeutic targets Nat Rev Drug Discov 2006, 5:235-246. 10.1038/nrd1982 16474316
31. Trubion Pharmaceuticals, SMIP™ therapeutics http://www.trubion.com/ products/technology/smip-therapeutics/
32. Ablynx, Nanobody® Platform http://www.ablynx.com/research/index.htm
33. Domantis Limited homepage http://www.domantis.com
34. Ward ES Gussow D Griffiths AD Jones PT Winter G Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli Nature 1989, 341:544-546. 10.1038/341544a0 2677748
35. Arana Therapeutics, ART621 - Phase II Trial Underway http://www.arana.com/inflammation_franchise_art621.htm
36. Milstein C Cuello AC Hybrid hybridomas and their use in immunohistochemistry Nature 1983, 305:537-540. 10.1038/305537a0 6137772
37. Suntharalingam G Perry MR Ward S Brett SJ Castello-Cortes A Brunner MD Panoskaltsis N Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 N Engl J Med 2006, 355:1018-1028. 10.1056/ NEJMoa063842 16908486
38. Natsume A In M Takamura H Nakagawa T Shimizu Y Kitajima K Wakitani M Ohta S Satoh M Shitara K Niwa R Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities Cancer Res 2008, 68:3863-3872. 10.1158/0008-5472.CAN-07-6297 18483271
39. Melmed GY Targan SR Yasothan U Hanicq D Kirkpatrick P Certolizumab pegol Nat Rev Drug Discov 2008, 7:641-642. 10.1038/nrd2654 18670430
40. Chatenoud L Ferran C Legendre C Franshimont P Reuter A Kreis H Bach J Clinical use of OKT3: The role of cytokine release and xenosensitization J Autoimmun 1988, 1:631-640. 10.1016/0896-8411(88)90054-6
41. Friend PJ Hale G Chatenoud L Rebello P Bradley J Thiru S Phillips JM Waldmann H Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection Transplantation 1999, 68:1632-1637. 10.1097/00007890-199912150-00005 10609938
42. Keymeulen B Vandemeulebroucke E Ziegler A Mathieu C Kaufman L Hale G Gorus F Goldman M Walter M Candon S Schandene L Crenier L De Block C Seigneurin JM De Pauw P Pierard D Weets I Rebello P Bird P Berrie E Frewin M Waldmann H Bach JF Pipeleers D Chatenoud L Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes N Engl J Med 2005, 352:2598-2608. 10.1056/NEJMoa043980 15972866
43. Utset TO Auger JA Peace D Zivin RA Xu D Jolliffe L Alegre ML Bluestone JA Clark MR Modified anti-CD3 therapy in psoriatic arthritis: A phase I/ II clinical trial J Rheumatol 2002, 29:1907-1913. 12233885
44. Plevy S Salzberg B Van Assche G Regueiro M Hommes D Sandborn W Hanauer S Targan S Mayer L Mahadevan U Frankel M Lowder J A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis Gastroenterology 2007, 133:1414-1422. 10.1053/j.gastro.2007.08.035 17920064
45. Ferrara C Brunker P Suter T Moser S Puntener U Umana P Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alphamannosidase II Biotechnol Bioeng 2006, 93:851-861. 10.1002/ bit.20777 16435400
46. Kanda Y Yamada T Mori K Okazaki A Inoue M Kitajima-Miyama K Kuni-Kamochi R Nakano R Yano K Kakita S Shitara K Satoh M Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types Glycobiology 2007, 17:104-118. 10.1093/glycob/cwl057 17012310
47. Davies J Jiang L Pan LZ LaBarre MJ Anderson D Reff M Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII Biotechnol Bioeng 2001, 74:288-294. 10.1002/bit.1119 11410853
48. Isaacs J Wing M Greenwood J Hazleman B Hale G Waldmann H A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans Clin Exp Immunol 1996, 106:427-433. 2200623 8973608 10.1046/ j.1365-2249.1996.d01-876.x
49. Bindon C Hale G Waldmann H Importance of antigen specificity for complement mediated lysis by monoclonal antibodies Eur J Immunol 1988, 18:1507-1514. 10.1002/eji.1830181006 2973413
50. Xia M Hale G Waldmann H Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen Mol Immunol 1993, 30:1089-1096. 10.1016/0161-5890(93)90155-5 8366859
51. Stebbings R Findlay L Edwards C Eastwood D Bird C North D Mistry Y Dilger P Liefooghe E Cludts I Fox B Tarrant G Robinson J Meager T Dolman C Thorpe SJ Bristow A Wadhwa M Thorpe R Poole S "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics J Immunol 2007, 179:3325-3331. 17709549
52. Bruggemann M Winter G Waldmann H Neuberger MS The immunogenicity of chimeric antibodies J Exp Med 1989, 170:2153-2157. 2189553 2584938 10.1084/jem.170.6.2153
53. Gorman SD Clark MR Humanisation of monoclonal antibodies for therapy Semin Immunol 1990, 2:457-466. 2104282
54. Chung CH Mirakhur B Chan E Le QT Berlin J Morse M Murphy BA Satinover SM Hosen J Mauro D Slebos RJ Zhou Q Gold D Hatley T Hicklin DJ Platts-Mills TA Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose N Engl J Med 2008, 358:1109-1117. 2361129 18337601 10.1056/NEJMoa074943
55. Eckardt K Casadevall N Pure red-cell aplasia due to anti-erythropoietin antibodies Nephrol Dial Transplant 2003, 18:865-869. 10.1093/ndt/gfg182 12686654
56. Mason U Aldrich J Breedveld F Davis C Elliott M Jackson M Jorgensen C Keystone E Levy R Tesser J Totoritis M Truneh A Weisman M Wiesenhutter C Yocum D Zhu J CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis J Rheumatol 2002, 29:220-229. 11838838
57. Genazzani AA Biggio G Caputi AP Del Tacca M Drago F Fantozzi R Canonico PL Biosimilar drugs: Concerns and opportunities BioDrugs 2007, 21:351-356. 10.2165/00063030-200721060-00003 18020619
58. Farid SS Process economics of industrial monoclonal antibody manufacture J Chromatogr A 2007, 848:8-18.
59. Elliott MJ Maini RN Feldmann M Kalden JR Antoni C Smolen JS Leeb B Breedveld FC Macfarlane JD Bijl H Woody JN Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis Lancet 1994, 344:1105-1110. 10.1016/S0140-6736(94)90628-9 7934491
60. Edwards J Szczepanski L Szechinski J Filipowicz-Sosnowska A Emery P Close D Stevens R Shaw T Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534 15201414
61. Maini RN Taylor PC Szechinski J Pavelka K Bröll J Balint G Emery P Raemen F Petersen J Smolen J Thomson D Kishimoto T CHARISMA Study Group Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate Arthritis Rheum 2006, 54:2817-2829. 10.1002/art.22033 16947782
62. Genovese MC Kaine JL Lowenstein MB Giudice JD Baldassare A Schechtman J Fudman E Kohen M Gujrathi S Trapp RG Sweiss NJ Spaniolo G Dummer W ACTION Study Group Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study Arthritis Rheum 2008, 58:2652-2661. 10.1002/art.23732 18759293
63. Dorner T Kaufmann J Wegener W Teoh N Goldenberg D Burmester G Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus Arthritis Res Ther 2006, 8:R74. 1526638 16630358 10.1186/ar1942
64. Keystone E Heijde D Mason D Jr Landewe R Vollenhoven RV Combe B Emery P Strand V Mease P Desai C Pavelka K Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 2008, 58:3319-3329. 10.1002/ art.23964 18975346
65. Herold KC Hagopian W Auger JA Poumian-Ruiz E Taylor L Donaldson D Gitelman SE Harlan DM Xu D Zivin RA Bluestone JA Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 2002, 346:1692-1698. 10.1056/NEJMoa012864 12037148
66. Weinblatt ME Keystone EC Furst DE Moreland LW Weisman MH Birbara CA Teoh LA Fischkoff SA Chartash EK Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial Arthritis Rheum 2003, 48:35-45. 10.1002/art.10697 12528101
67. Dorner T Burmester GR New approaches of B-cell-directed therapy: Beyond rituximab Curr Opin Rheumatol 2008, 20:263-268. 10.1097/ BOR.0b013e3282f5e08d 18388516
68. Furie R Stohl W Ginzler EM Becker M Mishra N Chatham W Merrill JT Weinstein A McCune WJ Zhong J Cai W Freimuth W Belimumab Study Group Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus Arthritis Res Ther 2008, 10:R109. 2592791 18786258 10.1186/ar2506
69. Keystone EC Genovese MC Klareskog L Hsia EC Hall ST Miranda PC Pazdur J Bae SC Palmer W Zrubek J Wiekowski M Visvanathan S Wu Z Rahman MU Golimumab, a human antibody to TNF-{alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: The GO-FORWARD Study Ann Rheum Dis 2008.
70. Weinblatt ME Kremer JM Bankhurst AD Bulpitt KJ Fleischmann RM Fox RI Jackson CG Lange M Burge DJ A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 1999, 340:253-259. 10.1056/ NEJM199901283400401 9920948
71. Genovese MC Becker JC Schiff M Luggen M Sherrer Y Kremer J Birbara C Box J Natarajan K Nuamah I Li T Aranda R Hagerty DT Dougados M Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition N Engl J Med 2005, 353:1114-1123. 10.1056/NEJMoa050524 16162882
72. Tak PP Thurlings RM Rossier C Nestorov I Dimic A Mircetic V Rischmueller M Nasonov E Shmidt E Emery P Munafo A Atacicept in patients with rheumatoid arthritis: Results of a multi-center, phase ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study Arthritis Rheum 2008, 58:61-72. 10.1002/art.23178 18163485